82 completed, 23 terminated, 6 unknown, 5 active not recruiting. 128 Phase 2, 31 Phase 1, 2 Phase 3.
Follow Sezary Syndrome: new trials by email Literature Review of Sezary Syndrome trials Research Report on Sezary Syndrome
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Golidocitinib in Patients With Mycosis Fungoides/Sézary Syndrome and T-Cell Large Granular Lymphocytic Leukemia Golidocitinib - Mycosis Fungoides/Sezary Syndrome, T-cell Large Granular Lymphocytic Leukemia | Phase 2 | Not yet recruiting | Washington University School of Medicine | 24 | 2026-12-31 | 2026-11-05 |
| A Study of MDSY-1240, a STAT3 Degrader, for the Treatment of Hematologic Malignancies and Advanced Solid Tumors MDSY-1240 - Triple-Negative Breast Cancer (TNBC), Gastric Cancer (GC) | Phase 1 / Phase 2 | Not yet recruiting | Medsyn Biopharma, LLC | 75 | 2026-11-01 | 2026-10-27 |
| Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma Aclarubicin, Cyclophosphamide, Vincristine - Cutaneous T-Cell Lymphoma Refractory, Cutaneous T-Cell Lymphoma, Relapsed | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Jiao Tong University School of Medicine | 37 | 2026-03-30 | 2026-04-17 |
| A Phase 2 Study of PTX 100 in Patients With Relapsed/Refractory CTCL PTX-100 - CTCL | Phase 2 | Recruiting | Prescient Therapeutics, Ltd. | 115 | 2025-03-28 | 2026-09-09 |
| Ritlecitinib in CTCL Ritlecitinib - CTCL, Mycosis Fungoides | Phase 2 | Terminated | Icahn School of Medicine at Mount Sinai | 7 | 2023-05-17 | 2025-07-18 |
| Extracorporeal Photopheresis and Mogamulizumab for the Treatment of Erythrodermic Cutaneous T Cell Lymphoma Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment - Folliculotropic Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Phase 2 | Recruiting | City of Hope Medical Center | 34 | 2022-10-19 | 2026-09-02 |
| Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome Gemcitabine, Pembrolizumab - Mycosis Fungoides, Mycosis Fungoides/Sezary Syndrome | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 14 | 2021-10-01 | 2026-11-02 |
| Mogamulizumab and Extracorporeal Photopheresis for the Treatment of Sezary Syndrome or Mycosis Fungoides Extracorporeal Photopheresis, Mogamulizumab, Quality-of-Life Assessment - Mycosis Fungoides, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma | Phase 1 / Phase 2 | Terminated | Emory University | 5 | 2021-04-21 | 2024-08-13 |
| Testing the Addition of an Anti-cancer Drug, Hu5F9-G4 (Magrolimab), to the Usual Chemotherapy Treatment (Mogamulizumab) in T-Cell (a Type of Immune Cell) Lymphoma That Has Returned After Treatment or Does Not Respond to Treatment Biospecimen Collection, Computed Tomography, Magrolimab - Mycosis Fungoides, Recurrent Mycosis Fungoides | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 8 | 2021-04-06 | 2025-10-16 |
| Study of Photopheresis in the Treatment of Erythrodermic MF and SS Methoxsalen, THERAKOS CELLEX Photopheresis System - Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome | Phase 2 | Withdrawn | European Organisation for Research and Treatment of Cancer - EORTC | 2020-12-01 | 2021-09-08 | |
| Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab Letermovir - B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 6 | 2020-09-15 | 2025-02-28 |
| Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome Mogamulizumab, LD TSEBT - Sezary Syndrome, Mycosis Fungoides | Phase 2 | Recruiting | Stanford University | 30 | 2020-03-30 | 2026-07-01 |
| Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides Pembrolizumab - Mycosis Fungoides, Sezary Syndrome | Phase 2 | Completed | Mayo Clinic | 9 | 2020-02-04 | 2025-08-29 |
| IPH4102/Lacutamab Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma IPH4102 - Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous | Phase 2 | Completed | Innate Pharma | 170 | 2019-05-22 | 2026-04-29 |
| A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS) Pembrolizumab, Radiotherapy - Cutaneous T Cell Lymphoma, Mycosis Fungoides/Sezary Syndrome | Phase 2 | Active not recruiting | University College, London | 46 | 2019-01-15 | 2024-12-09 |
| PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL) Atezolizumab - Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome | Phase 2 | Terminated | European Organisation for Research and Treatment of Cancer - EORTC | 26 | 2018-09-24 | 2024-02-22 |
| Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients brentuximab vedotin - Mycosis Fungoides, Lymphomatoid Papulosis | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 51 | 2018-07-03 | 2026-11-06 |
| Doxycycline for the Treatment of Cutaneous T-Cell Lymphoma Doxycycline monohydrate - Cutaneous T-cell Lymphoma, Mycosis Fungoides | Phase 2 | Terminated | Rochester General Hospital | 1 | 2018-02-06 | 2021-04-27 |
| Testing the Combination of Two Experimental Drugs MK-3475 (Pembrolizumab) and Interferon-gamma for the Treatment of Mycosis Fungoides and Sézary Syndrome and Advanced Synovial Sarcoma Interferon Gamma-1b, Laboratory Biomarker Analysis, Pembrolizumab - Metastatic Myxoid Liposarcoma, Metastatic Round Cell Liposarcoma | Phase 2 | Completed | National Cancer Institute (NCI) | 28 | 2017-12-14 | 2023-10-25 |
| Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers Biopsy Procedure, Biospecimen Collection, Computed Tomography - Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 68 | 2017-09-27 | 2026-11-18 |
Showing 20 of 128. Sign in to see all of them.
Mycosis Fungoides (125) · Lymphoma, T-Cell, Cutaneous (113) · Leukemia, Lymphocytic, Chronic, B-Cell (67) · Lymphoma, B-Cell, Marginal Zone (67) · Lymphoma, Follicular (67) · Lymphoma, Large B-Cell, Diffuse (66) · Lymphoma, Non-Hodgkin (66) · Lymphoma, Mantle-Cell (64) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (63) · Hodgkin Disease (61) · Lymphoma, Large-Cell, Immunoblastic (59) · Burkitt Lymphoma (58) · Lymphoma (50) · Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (50)
Hemic and Lymphatic Diseases (128) · Immune System Diseases (128) · Immunoproliferative Disorders (128) · Lymphatic Diseases (128) · Neoplasms by Histologic Type (128) · Neoplasms (124) · Lymphoma, T-Cell (122) · Lymphoproliferative Disorders (120) · Lymphoma (78) · Hematologic Diseases (76) · Leukemia, Lymphoid (76) · Disease Attributes (71) · Pathologic Processes (71) · Pathological Conditions, Signs and Symptoms (71) · Lymphoma, B-Cell (69)
fludarabine phosphate (22) · Mycophenolic Acid (19) · Peripheral Blood Stem Cell Transplantation (18) · Tacrolimus (17) · Cyclophosphamide (16) · Whole-Body Irradiation (16) · Cyclosporine (14) · Antilymphocyte Serum (12) · Busulfan (12) · Methotrexate (12) · Radiotherapy (8) · Rituximab (7) · Alemtuzumab (6) · Etoposide (6) · Bexarotene (5)
Fred Hutchinson Cancer Center (19) · National Cancer Institute (NCI) (13) · Northwestern University (10) · Mayo Clinic (7) · European Organisation for Research and Treatment of Cancer - EORTC (5) · Case Comprehensive Cancer Center (4) · City of Hope Medical Center (4) · Memorial Sloan Kettering Cancer Center (4) · Roswell Park Cancer Institute (3) · UNC Lineberger Comprehensive Cancer Center (3) · Genmab (2) · Herbert Irving Comprehensive Cancer Center (2) · Jonsson Comprehensive Cancer Center (2) · M.D. Anderson Cancer Center (2) · Novartis Pharmaceuticals (2)
United States (109) · Italy (11) · Germany (8) · Switzerland (8) · France (7) · Belgium (5) · United Kingdom (5) · Austria (4) · Spain (4) · Australia (3) · Canada (2) · Poland (2) · Argentina (1) · China (1) · Finland (1)
Timothy M. Kuzel, MD (4) · Brenda Sandmaier (3) · Ajay Gopal (2) · Alison Moskowitz, MD (2) · David G. Savage, MD (2) · David Maloney (2) · Madeleine Duvic, MD (2) · Robert Knobler (2) · Steven M. Horwitz, MD (2) · Thomas C. Shea, MD (2) · Thomas E. Witzig, MD (2) · Tim Illidge (2) · Youn H Kim, MD (2) · Adam Petrich, MD (1)
PMID 32499241, PMID 32632956, PMID 12543862, PMID 15107815, PMID 17515522, PMID 18327587, PMID 19170225, PMID 19199905, PMID 19826128, PMID 19841031, PMID 19900571, PMID 20142598, PMID 20166206, PMID 20229590, PMID 21135857, PMID 21355097, PMID 22981498, PMID 23045580, PMID 24241210, PMID 24285015, PMID 24307695, PMID 24335103, PMID 25795722, PMID 25891346, PMID 25921059, PMID 26195720, PMID 26210442, PMID 26213141, PMID 26764356, PMID 28199478, PMID 28264616, PMID 28314788, PMID 31532724, PMID 31689242, PMID 32269142, PMID 32941647, PMID 33072126, PMID 33236943, PMID 34795254, PMID 37327113, PMID 38664936, PMID 39951620, PMID 41651641
P30CA015704 (9), P01CA018029 (3), P30CA008748 (3), P30CA015083 (3), P30CA043703 (3), 2018 (2), P01CA078902 (2), P30CA016086 (2), P30CA033572 (2), P30CA060553 (2), U01CA154967 (2), 2004 (1), 2016 (1), 2017 (1), 2023 (1)